Future meetings
LASA Spring Scientific Meeting It has been decided not to hold a Spring meeting this year, but to concentrate on the meetings of the three LASA sections which will be held at this time. All three sections will be holding meetings in April or May. The Management Section hopes to be able to review new barrier and containment techniques and facili ties.
For further information on the details of the programme, please contact the convenors (see front pages).
SECAL-3rd
Biannual Meeting 
19-20 May 1994
The highly successful and popular two-day workshop dealing with anaesthesia of laboratory animals will again be held at the University of Newcastle upon Tyne on 19-20 May 1994. The workshop is open to veterinary surgeons with an interest in laboratory animals, animal technicians who either have Membership status with the Institute of Animal Technology or who will be sitting the Membership examination in 1993 and research workers wishing to obtain training in anaesthesia. The course will consist of formal lectures and practical tuition. Numbers of participants will be limited. Detailed course notes will be provided. The course content will cover the relevant section of Module 4 of the Home Office Guidelines. The course fee, inclusive of all catering, is £145 and overnight accommodation can be arranged if required. Further details are available from Dr P A Flecknell, Comparative Biology Centre, Medical School, Framlington Place, Newcastle upon Tyne, NE2 4HH, UK. Tel: 091 222 6715.
Course on Laboratory Animal Science
Monday-Friday 6-17 Tune 1994 (Utrecht, Netherlands) A 2-week intensive course on laboratory animal science will be organized at the Department of Laboratory Animal Science -Utrecht, The Netherlands in June 1994. The objective of this course is to present basic facts and principles that are essential for the humane use of animals and for the quality of research. The contents of the course are in line with recommendations of the Federation of European Laboratory Animal Science Associations (FELASA) regarding the training of the young scientist whose research involves the use of vertebrate animals.
The course may also be of interest for those who intend to set up a similar course at their location. For this purpose, during the course the acquisition of teaching materials can be discussed with the course committee.
For information and application forms please contact: Mrs Marianne Albers, Department of laboratory Animals (1994) 28. [183] [184] [185] [186] [187] [188] [189] [190] [191] [192] Laboratory Animal Science, Faculty of Veterinary Medicine, PO Box 80.166, 3508 TD Utrecht, The Netherlands
Announcements
The first UFAW Hume Fellowship in Animal WeUare The Universities Federation for Animal Welfare, in commemoration of its founder, Major Charles W. Hume, is pleased to announce that the fellowship has been awarded to Professor John Webster of the Department of Animal Husbandry, School of Veterinary Sciences, Bristol University.
The fellowship will enable Dr Webster to write a book entitled 'A Cool Eye Towards Eden' -being a constructive approach to the problem of man's dominion over the animals.
Dr Ian Natoff
Dr Ian Natoff has now left Roche and has asked for the following announcement to be made. Dr Ian Natoff, formerly Home Office Liaison Officer with Roche Products Limited, has formed his own Consultancy, Endive Associates, from 1 January 1994. Endive will advise, assess and assist in the preparation of applications for project licences and related matters dealt with by E Division of the Home Office. Endive Associates may be contacted on (Tel): 0923-856030; [Faxl: 0923-854748.
Laboratory Animals Ltd Training Bursaries
Laboratory Animals Ltd wishes to encourage research workers to gain additional training and expertise in laboratory animal science. In particular, the Company wishes to encourage visits between European states, so that a broader perspective of issues such as the need for refinement of research procedures can be gained. As an initial step, the Company is making available a small number of bursaries during 1994. These bursaries are intended to finance attendance at short training courses (up to 14 days), for example those held at the University of Utrecht, and those available at a number of research institutes in the United Kingdom.
Further details, and application forms, can be obtained from: Dr P. A. Flecknell, Director, Comparative Biology Centre, Medical School, Framlington Place, Newcastle upon Tyne, NE2 4HH.
News from the Associations
Nederlandse Vereniging voor Proefdierkunde (NVP) The 1993 Spring symposium of NVP was devoted to the role of laboratory animals in immunology. The following are summaries of papers presented:
Notes and comments
(11 Code of practice for the immunization of laboratory animals. By P. de Greeve, Veterinary Public Health Inspectorate, Department of Animal Experimentation, Rijswijk, The Netherlands.
The production of antibodies involves considerable distress for the animals used. The extent of the distress is determined by the use of an adjuvant, the nature of the antigen, the doses, the volume of the inoculate and the route of immunization. It is the task of the Veterinary Inspectorate to investigate any possibility to minimize the distress. In 1990 the Veterinary Inspectorate established the Working Party on Immunization Procedures. The task of the working party was: -to make an inventory of the adjuvants and immunization procedures which have been used in Dutch research institutes; -to judge critically the distress involved; -to formulate proposals for additional research with the aim to minimize the distress; -and last but not least: to draft a Code of practice for the immunization of laboratory animals.
Recently the working party has presented the Code of practice for the immunization of laboratory animals. The Code is meant to stimulate a responsible use of adjuvants to guarantee the well-being of the animals concerned as much as possible. The Code is drafted on the basis of the current state-of-theart. If necessary, it will be adapted to new scientific developments. The Inspectorate is convinced that the Code can help researchers to select their method of immunization. In addition, the Code will guide ethical committees judging the admissibility of animal experiments. The use of adjuvants causing distress in animals, such as Freund's complete adjuvant, should be justified in the protocol that is presented to the ethical committee. The Inspectorate will closely monitor the actual acceptation of the Code.
(2) The use of adjuvants in The Netherlands. By W. de Leeuw, Veterinary Public Health Inspectorate, Department of Animal Experimentation, Rijswijk, The Netherlands.
In 1991 the Dutch Working Party on Immunization Procedures conducted a survey to investigate which immunization procedures and adjuvants are being used in Dutch research institutes. There appears to be a great variety in immunization procedures used in these institutes. Adjuvants are being used by 94% of the 111 responding researchers interviewed (123 researchers in 33 of the about 100 Dutch institutes were sent a questionnaire) who immunized laboratory animals; 74% of these researchers use Freund's complete adjuvant (FCA). The researchers use the following species for immunization: rabbit (41%), mouse (37%), rat 115%), hamster [1%), guinea pig (1%), pig (0.5%1, chicken [1%), primate (0.5%). Most of the researchers using FCA in rabbits choose the subcutaneous (40%) or the intramuscular (13%1 route of immunization or both routes [30%). Rats are predominantly immunized subcutaneously (26%), intraperitoneally [37%) or in the footpad (21%). Mice are predominantly immunized subcutaneously (15%) or intraperitoneally (68%). All the researchers immunizing in the footpad are of the opinion that this technique induces severe discomfort.
According to 73% of the researchers using FCA, this adjuvant causes moderate or severe discomfort. With the exception of oil in water emulsions and intrasplenal immunization none of the other adjuvants and immunization procedures is considered to cause severe discomfort. Only a few researchers have done experiments to compare the effectiveness and side effects of several adjuvants or immunization procedures. Most of them seem to cling to familiar immunization schemes. The results of the survey indicate that usage of FCA is often based on habits and protocols persisting in the institute.
(3) Application of adjuvants: sense and nonsense. By E. Claassen and W. Boersma, Laboratory for Immunology and Medical Microbiology, TNO Medical Biological Laboratory, Rijswijk, The Netherlands.
In biotechnological research and diagnostics a drastic increase in the production and use of poly-and monoclonal antibodies against the most exotic determinants is observed. With weak immunogens the stimulation of B-and Tcells by antigen alone is not enough to obtain good antibody titres. In those instances the immune system needs an extra push consisting of a general non-specific potentiation (adjuvation). Adjuvation can also be necessary in the induction of cellular immunity, e.g. for generating cytotoxic T-cells.
To elicit an immune response, the antigen can be delivered in various forms: free antigen, antigen coupled to a carrier, antigen supported by a vehicle. All these forms of the antigen experience the same potentiation by an adjuvant. The potentiation which is offered by an adjuvant is different from that offered by the binding of a low or non immunogenic antigen to a carrier. A carrier, in most cases a protein, is immunogenic by itself and can offer T-cell help for antigens with intrinsic low immunogenicity when these are linked to the carrier. The choice of an optimal carrier and/or T-cell epitope can result in the use of less strong adjuvants.
Vehicles transport the antigen but cannot offer T-cell help (they have no T-cell epitopes). Vehicles are usually non-immunogenic and relatively inert: alum, mineral oils, latex or sepharose beads, nitrocellulose, liposomes or 185 pluron-acid polymers; (the latter two are also adjuvants). The well known Freund's complete adjuvant IFCA)consists of an oil phase (mostly paraffin) admixed with dead Mycobacteriae. The oil functions both as vehicle and as a depot and attracts inflammatory cells (e.g. macrophages, T-cells) which brings the antigen into close contact with the immune system. The use of FCA in experimental animals causes severe pain. In addition the immune response against the bacterial component can be so strong that it suppresses the (wanted) response against the admixed antigen. Second generation adjuvants therefore do not contain the intact Mycobacteria but only parts of these (e.g. lipid-A, cellwall components) or less mitogenic bacteriae. Many of these adjuvants still possess unwanted side effects and the efficiency is not always optimal. Third generation adjuvants are entirely synthetic compounds: synthetic oils, DDA, liposomes, ISCOMs, non-ionic block polymers, saponins, antibodies, cytokines and polyanions. A more directed targeting and stimulation of the immune system is possible with these adjuvants. However, a new universal adjuvant that stimulates the immune system to maximum responses, of the desired type, against any admixed antigen is still not available.
The right balance of adjuvant and antigen and the choice for a specific response type [humoral, isotype, cellular) against the antigen, is crucial to obtain an optimal specific immune response. In many cases too strong adjuvants are used. These result in immune responses but cause discomfort to the laboratory animal. Often weaker adjuvants actually favour the antigenspecific part of the response.
Specific immunization routes are often optimal only for a given combination of antigen, carrier, vehicle and adjuvant. The route is of utmost importance for both the extent and the type (isotype and/or humoral vs cellular) of the response. Furthermore the time schedule used for booster immunizations is important and depends on the type of antigen, the desired effect and the species used. When boostering for cell fusions [e.g. hybridomas), the intraperitoneal use of oils gives problems in that the oil reaches the spleen and contaminates the cell suspensions. Well chosen optimal combinations of adjuvant, antigen, animal species, time course and route make the use of strong ( The purpose of any veterinary vaccination programme is to prevent the occurrence of disease by preventing or limiting infection. In general two types of vaccines exist: live and inactivated vaccines, both with unique characteristics. The final choice of a vaccine will be determined by a combination of factors such as efficacy, availability, price and safety. Live vaccines can be highly effective and very cheap for mass application but they have the potential danger of pathogenicity and genetic instablity. Inactivated vaccines do not have these properties but they cannot replicate in the host and therefore need additional help in the form of an adjuvant in order to induce a protective immune response. Adjuvants are essential ingredients of inactivated vaccines. At the present time numerous adjuvants are knoWD, while only a few are currently in use for veterinary vaccines: mineral oil emulsions, aluminum compounds and saponin. In order to find new adjuvants to improve existing vaccines or for vaccines in the developmental stage, various animal screening models are used. The induction of effective B-and T-cell responses to antigens usually requires the assistance of so-called adjuvants. For this purpose Freund's adjuvant (FA) is frequently used in laboratory animals. However, administration of Freund's adjuvant induces various adverse effects including local inflammation, sterile abscesses and necrotising dermatitis. It is therefore necessary to consider the use of alternative adjuvants. We have evaluated in rabbits several types of adjuvants as an alternative to FA with regard to clinical, immunological and pathological parameters: FA (both incomplete and complete), Specol (a water-in-oil emulsion), ISCOM, RIBI (MPL + TDM + CWSI and TiterMax (a non-ionic block polymer surfactant). Each of the adjuvants was combined with three different types of antigens: a synthetic peptide, a glycolipid and a particular antigen and animals were immunized by intramuscular and subcutaneous routes. The animals did not appear to be severely or chronically impaired by the experiment. After injection of the RIBI adjuvant side effects of the same severity as with FA were induced, while low antibody titres were produced. TiterMax caused little and ISCOM no side effects, while antibody responses were very low. Specol had far less adverse effects than FA. However, Specol had immunostimulating properties of the same level as FA. In additional experiments the effect of injected volume of FA on side effects and Notes and comments antibody titres and the effect of intradermal (i.d.) adjuvant administration were studied. Immunization of rabbits with a total of 0.5 ml FA delivered at different sites did not increase the immune response over the results after injection at one site. However, side effects were seen in all the animals. After i.d. injection of FA or RIBI, adverse effects such as necrosis were found. No side effects occurred after i.d. injection of Specol or TiterMax.
From the studies it is concluded that Specol might be a possible alternative to FA.
(6) Chicken eggs: an alternative source of antibody production. By J. de Witte, Department of Endocrinology, Catholic University Nijmegen, The Netherlands.
It has been known for a long time that birds accumulate a considerable amount of antibodies in the egg yolk, providing immunological protection until the offspring's defence system is completely developed. The polyclonal antibodies in the chicken egg yolk represent a distinct class of immunoglobulins, different from mammalian IgG, designated as IgY (Y= yolk). Immunization of chickens offers a good alternative to the production of antisera, nowadays frequently raised in mammals (rabbit, sheep, goat, pony). The immunization is performed by intramuscular injection (M. pectoralis) with the immunogen, preferably in an emulsion with Freund's complete adjuvant. A limited amount of immunogen [approximately 10 J.'g) is sufficient; conjugation to a carrier protein may be necessary if the antigen's molecular weight is less than 5000-10 000 Dalton. A single injection of immunogen results in relative high antibody titres in the serum, which remain at elevated levels over a prolonged period of time. The antibody titre in yolk is equal to or greater than that of the corresponding serum and the amount of purified antibodies isolated from a few eggs is even higher than the quantity obtained by immunization and bleeding of one rabbit.
Because of the phylogenetic distance between birds and mammals, the use of non-mammalian species facilitates antibody production against evolutionary conserved [mammalian) proteins, whereas rabbits for example sometimes fail to respond to these. Collecting eggs for IgY extraction is non-invasive, much less stressful to the animals and easier than obtaining blood samples or bleeding the animals. Yolk antibodies are acid and heat stable, which offers the possibility to use them for prophylaxis and therapy of infectious intestinal diseases in veterinary and perhaps also human medicine. Beside these therapeutic applications, specific poly clonal antibodies extracted from egg yolk are applicable in modern diagnostic immunology, in the same fashion as antibodies produced in mammals.
In Immunomodulation by microorganisms: the importance of healthy experimental animals. By P. J. Heidt, Department of Infectious Diseases, TNO Medical Biological Laboratory, Rijswijk, The Netherlands.
Within the biomedical research area there is an increasing tendency to lower the number of experimental animals used. This goal can be reached by eliminating those factors that can negatively influence the outcome of experiments. One of the most important factors is the health status of the experimental animals. Therefore, the presence of a health surveillance programme as well as a number of measures that result from such a programme are essential to carry out high-quality research. The importance of a health surveillance programme is stressed by the fact that a variety of murine pathogens, which normally should not be present, are still being detected in many colonies throughout the world. Usually these microorganisms cause subclinical infections. However, this situation can change dramatically under circumstances of experimental stress, and may result in increased morbidity and mortality. Experimental animals for high-quality research should therefore be free from pathogenic and potentially pathogenic microorganisms, such as Sendai virus, mouse hepatitis virus, Salmonella, Pseudomonas, Pneumocystis, Hexamita, etc. Beside the fact that these organisms can cause fatal infections in immunocompromised animals, they can also influence the immune system in a way that immunological research becomes impossible or that resulting data are likely to be misinterpreted. Every large breeding or research facility should therefore run a health surveillance programme that is capable of detecting at least one or more infected animals within a population, based on microbiological, serological and pathological examination of a randomly drawn, properly sized sample.
(8) Social stress and the immune system. By J Koolhaas, Department of Animal Physiology, University of Groningen, The Netherlands.
Many of the laboratory animal species, such as rats and mice, live under natural conditions in rather complex social structures. Within a population, the males usually form a social hierarchy. These social interactions strongly affect stress-related neuroendocrine and autonomic mechanisms. Due to the interaction of these stress mechanisms with the immune system, these social factors affect the immunological status of the animals as well. For instance, social isolation significantly alters both cellular and humoral immunity. In several studies it has been shown that the social hierarchy is reflected in the reactivity of the immune system. In dominant and subdominant males usually an enhanced in vitro lymphocyte proliferation response to mitogenic stimulation 187 is found, in comparison to subordinate animals. A similar differentiation in immunological reactivity is also seen in animals which were raised under standard laboratory conditions. Behavioural and physiological studies show that such an individual variation in groups of male rats and mice is based upon a differentiation in the way in which animals cope both behaviourally and physiologically with environmental challenges. Apart from genetic and ontogenetic factors, also adult social experiences contribute to the individual differentiation in behaviour and immunology. Loss of social status due to defeat seems to result in immunological changes that may last for weeks. These effects of the social environment on the immune system implicate that experimental inference with social behaviour may be an important confounding factor in many immunological experiments.
Gesellschaft fUr Versuchstierkunde (GV-SOLAS) Annual Report, 1992 Report, -1993 Since the last general assembly which took place in Salzburg on 27 September 1992 the membership has increased by two to a total of 406 ordinary, 27 extraordinary and 73 sponsoring members. TO'our deep regret we learned of the decrease of our two members R Haysmanova and Professor Arnold Spiegel who contributed significantly to the early development of Laboratory Animal Science.
The Executive Board met once in Basle for a two-day meeting and three times in Heidelberg for single day meetings. In addition a workshop meeting together with the Advisory Board was organized in Berlin on the 20 and 21 September 1993. The work of the board included supporting efforts to unite animal welfare officers throughout the country, in the preparation of a statement of position together with the Committee for Education and Correct Housing concerning the accommodation of laboratory animals and in the completion of a list of comments concerning the proposalsof 12February 1993 for a revision of the German Animal Welfare Act. In addition an appeal was lodged to change the legislation on gene technology so as to give laboratory animal scientists the competence to breed transgenic strains.
The Committee for Education and Correct Housing edited guidelines on the construction and organization of laboratory animal facilities as an extension of publication No.1. The recommendation will be published by the Gustav Fischer Verlag. After discussions with the convenor and the members it was decided to propose a division into two separate committees. This seemed necessary in view of the increasing importance of both fields the committee had hitherto covered.
The old regulations for awarding the title of 'Expert in Laboratory Animal Science, GV-SOLAS'
Invited referees
The Editorial Board is most grateful to the many referees who have helped in assessing papers submitted to Laboratory Animals. Amongst those who assisted during 1993 are: necessary to initiate a special meeting during the year. It should also be mentioned that GV-SOLAS has recently been included in the Public List of Registered Associations and their Representatives at the Bundestag.
The financial situation of the Society is sound. The meeting in Salzburg was able to contribute a respectable sum to our treasurer. We should like to thank the organizers and sponsors for their efforts.
At the general assembly on 23 September 1993 Professor Dr Hans Joachim Hackbarth was elected as next president of GV-SOLAS, Dr Annemarie Treiber replaced Professor Bert van Zutphen as vice-president and Dr Christiane Herweg was elected as new secretary in place of Dr Ueli Miirki. Dr Jilge and Dr Pittermann will be new members of the Executive Board from 1994 on. The former Committee for Education and Correct Housing was split into two separate groups which will be led by Dr Nebendahl (Education) and Dr Militzer (Animal Accommodation). The new regulations for the award of a GV-SOLAS prize and for the recognition of the title 'Expert in Laboratory Animal Science GV-SOLAS' were adopted. Professor Walter Rossbach, who has served GV-SOLAS for many years on the board (secretary) and advisory board has left the advisory board since his time of service is terminated. We owe him many thanks for his very active engagement. He has been replaced by Dr H. Weber.
It was announced that the next GV-SOLAS Scientific Meeting will take place in Munich from 13-15 September 1994; an invitation was received to organize the 1995 meeting in Aachen and 1996 will see a FELASA meeting in Basle.
H. Weber President were also revised. The requirements have now become more stringent with regard to experience obtained with various species and acceptance of institutes in which the candidates work.
The work of the Committee on Hygiene was marked by the diversity of subjects covered. Special mention should be made of the publication on Immunization, the preparation of an 'Atlas' and the 'ring-experiment' on quality control of microbiological diagnostic laboratories.
The Committee on Nutrition prepared two information brochures on luxury consumption and dietary components and their use for laboratory animals.
The efforts to improve our relationships with other scientific associations concerned with animal experimentation deserve special mention. At the general assembly the board was encouraged to further pursue its aims. It was decided to follow the developments in the Union of German Biological Societies IUD-BioI and take up closer contacts with the 'Gesellschaft zur Fi.irderung der Biomedizinischen Forschung'. Professor Herberg will be able to join the board of this society as guest. Finally the board also stated its intention to improve public relations as outlined in the protocol of the workshop meeting in Breukelen 1992.
Some of our Executive and Advisory Board members were involved in various activities of FELASA. The president of GV-SOLAS was able to participate at the meeting of the multilateral consultation meeting of parties to the European Convention for the Protection of Vertebrate Animals used for Experimental or other Scientific Purposes as one of the delegates of the observer group of FELASA. It is encouraging to note that FELASA has gained recognition as a competent group for consultation within the EC and the Council of Europe. 
